Filters close
9-Apr-2018 2:05 PM EDT
When Prostate Cancer Reaches Bone, Bone Cells May Drive Overall Growth of the Disease
University of Colorado Cancer Center

When prostate cancer metastasizes to bone, it can become especially dangerous – CU Cancer Center study at AACR18 hints at why: Cells involved in these bone metastases may release signals that drive the progression of the disease.

9-Apr-2018 1:05 PM EDT
Beyond PD-L1: Taking Away TIM3 and Tregs Stops Cancer Regrowth After Immunotherapy
University of Colorado Cancer Center

CU Cancer Center study presented at AACR18 shows that TIM3 and/or increased regulatory T cells (Tregs) within a tumor may help cancers inactivate immune system killer T cells that would otherwise identify and attack the cancer.

9-Apr-2018 3:05 PM EDT
How Do Melanoma Cells Survive Drug Treatment Long Enough to Acquire Drug Resistance?
University of Colorado Cancer Center

University of Colorado Cancer Center study presented at AACR 2018 shows that even within three days of treatment, melanoma cells find a way to activate MEK – not with mutations, but with a more flexible and temporary way to allow these cancer cells to signal through the MAPK pathway even in the presence of BRAF inhibition.

Released: 19-Mar-2018 4:00 PM EDT
Cancer Comes Back All Jacked Up on Stem Cells
University of Colorado Cancer Center

Three tumor samples collected over time from a single patient show how cancer evolves in response to treatment.

Released: 2-Mar-2018 8:05 AM EST
Here's How Viruses Inactivate the Immune System, Causing Cancer
University of Colorado Cancer Center

"The same mechanisms that viruses use to cause cancer may be key in combating tumors with immune-based therapies or in keeping cancer from developing in the first place," says Sharon Kuss-Duerkop, PhD.

Released: 30-Jan-2018 11:05 AM EST
Expert Panel Issues New Guidelines for Lung Cancer Molecular Testing
University of Colorado Cancer Center

Experts from three major organizations add ROS1 to list of tests matching lung cancer with targeted treatments.

Released: 29-Jan-2018 11:05 AM EST
Study Suggests PD-1 Inhibitors Against Aggressive Pediatric Brain Cancer Subtype
University of Colorado Cancer Center

A University of Colorado Cancer Center study published in the journal Pediatric Blood Cancers lays the scientific groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.

Released: 22-Jan-2018 11:05 AM EST
Microbiome Predicts Blood Infections in Pediatric Cancer Patients
University of Colorado Cancer Center

Patients who developed bloodstream infections had significantly reduced microbiome diversity than patients who remained free of infection.

Released: 19-Jan-2018 8:05 AM EST
Treatment-Related Mortality of Surgery vs. Targeted Radiation in Early Lung Cancer Patients
University of Colorado Cancer Center

Among patients older than 80 years, 3.9 percent receiving surgery passed away within the 30-day post-treatment window, compared with 0.9 percent of patients receiving focused radiation.

Released: 19-Dec-2017 11:05 AM EST
Radiosurgery vs. Whole-Brain Radiation in Lung Cancer Patients with Multiple Brain Metastases
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that radiosurgery may effectively treat brain metastases associated with certain types of lung cancer, even when the number of metastases exceeds established norms.

Released: 13-Dec-2017 11:05 AM EST
Even Smokers May Benefit From Targeted Lung Cancer Treatments
University of Colorado Cancer Center

When a targetable genetic alteration is present, matching the alteration with the appropriate targeted therapy is associated with a survival benefit of 1.5 years, regardless of smoking history.

Released: 30-Nov-2017 4:10 PM EST
Some Chemicals in Smoke May Be Even More Dangerous Than Previously Thought
University of Colorado Cancer Center

Though most “low molecular weight polycyclic aromatic hydrocarbons” (LMW PAHs) have not been shown to cause cancer alone, the study shows that in common combinations, these chemicals can help to spark the disease.

Released: 7-Nov-2017 11:05 AM EST
Study Finds a New Way to Shut Down Cancer Cells’ Ability to Consume Glucose
University of Colorado Cancer Center

Many cancers depend on glucose consumption for energy, but good pharmacological targets to stop cancers’ ability to uptake and metabolize glucose are missing. CU Cancer Center study finally identifies a way to restrict the ability of cancer to use glucose for energy.

Released: 6-Nov-2017 4:35 PM EST
Important New Insights Into RECIST Criteria Measuring Cancer’s Response to Treatment
University of Colorado Cancer Center

CU Cancer Center study examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.

Released: 1-Nov-2017 11:05 AM EDT
In the Lab and in the Clinic, Alisertib with TAK-228 Excels Against Solid Tumors, Including Triple-Negative Breast Cancer
University of Colorado Cancer Center

Two University of Colorado Cancer Center studies presented this weekend at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting show that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative breast cancer and solid tumors than either drug alone.

Released: 24-Oct-2017 12:05 PM EDT
Tarloxitinib Puts Tumor-Seeking Tail on Anti-EGFR Drug to Precisely Target Lung Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center study being presented October 28 at the AACR-NCI-EORTC International Conference on Molecular Targets: By pairing an anti-EGFR drug with a “tail” that only activates the drug when it is very near tumor cells, tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues.

Released: 23-Oct-2017 2:05 PM EDT
Lung Cancer Driver ALK-Fusion Found in Melanoma
University of Colorado Cancer Center

University of Colorado Cancer Center study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib – both FDA approved to treat ALK-positive lung cancer – the tumor responded dramatically.

Released: 18-Oct-2017 4:05 PM EDT
Researchers Watch in Real Time as Fat-Encased Drug Nanoparticles Invade Skin Cells
University of Colorado Cancer Center

Some anti-cancer drugs are encapsulated to allow gradual release, spreading their effect over a longer time. For example, one formulation of the chemotherapy doxorubicin ( the FDA-approved drug Doxil®) encloses molecules of the drug in fatty nano-spheres called liposomes, which allows the drug to circulate longer in the blood.

Released: 9-Oct-2017 2:05 PM EDT
P53 “Master Switch” Remains Top Target in Gene Signaling Network Controlling Cancer Suppression
University of Colorado Cancer Center

“People have always been after the silver bullet against cancer and there are few things that are as relevant across cancer types as p53. Now the question is what is the best approach to harness it,” says senior author Joaquin Espinosa, PhD.

Released: 6-Sep-2017 12:05 PM EDT
Blood Tumor Markers May Warn When Lung Cancer Patients Are Progressing on Targeted Treatments
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that monitoring levels of blood tumor markers may predict when a lung cancer patient is progressing on targeted treatments.

Released: 30-Aug-2017 11:05 AM EDT
New Approach to Genetic Testing Matches Lung Cancer Patient with Life-Saving Drug
University of Colorado Cancer Center

A University of Colorado Cancer Center case study published today in the journal JCO Precision Oncology tests for alterations in many genes simultaneously, matching stage IV lung cancer patient with life-saving drug

Released: 23-Aug-2017 12:05 PM EDT
On the Other Hand, the Immune System Can Also CAUSE Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center paper describes how immune response designed to scramble HPV DNA can scramble human DNA as well, sometimes in ways that cause cancer.

Released: 14-Aug-2017 1:05 PM EDT
Does Stronger Initial Response to Cancer Treatment Predict Longer Overall Survival?
University of Colorado Cancer Center

It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer.

Released: 7-Aug-2017 12:05 PM EDT
Fat Rats Show Why Breast Cancer May Be More Aggressive in Patients with Obesity
University of Colorado Cancer Center

In an animal model of obesity and breast cancer, tumor cells in obese animals but not lean animals had especially sensitive androgen receptors, allowing these cells to magnify growth signals from the hormone testosterone.

Released: 31-Jul-2017 12:05 PM EDT
Refuting the Idea That Mutations Cause Cancer
University of Colorado Cancer Center

Writing today in the journal Cancer Research, James DeGregori, PhD, deputy director of the University of Colorado Cancer Center offers evidence that it is forces of evolution driven by natural selection acting in the ecosystem of the body that, in the presence of tissue damage, allow cells with dangerous mutations to thrive.

Released: 27-Jul-2017 11:05 AM EDT
Study Finds Breast Cancer Driver, HER2, in 3 Percent of Lung Cancers
University of Colorado Cancer Center

The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one percent of these patients were never-smokers, with a median age of 62. The gene HER2 has been known as a breast cancer driver, with therapies approved to target HER2 mutations in this setting.

Released: 25-Jul-2017 4:05 PM EDT
CU Cancer Center Study May Explain Failure of Retinoic Acid Trials Against Breast Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining failure of retinoic acid trials against breast cancer and offers a possible strategy for their use.

Released: 12-Jul-2017 11:05 AM EDT
Thomas Flaig, MD, Named Chair of NCCN Bladder Cancer Panel
University of Colorado Cancer Center

University of Colorado Cancer Center's Thomas Flaig, MD, has been named chair of the NCCN Clinical Practice Guidelines in Oncology Panel for Bladder Cancer, a group of 34 multidisciplinary bladder experts from NCCN Member Institutions that will influence the future direction of care for the disease.

Released: 10-Jul-2017 11:05 AM EDT
NEJM Case Reports Show Promise of Cancer Immunotherapy to Treat Rare Lymphoma
University of Colorado Cancer Center

Three case reports published in the New England Journal of Medicine demonstrate the promise of cancer immunotherapy in gray zone lymphoma, potentially paving the way for clinical trials utilizing this strategy in this and related conditions.

Released: 14-Jun-2017 3:05 PM EDT
CU Cancer Center Chemoprevention Trial Hopes to Stop Lung Cancer Before It Starts
University of Colorado Cancer Center

Ongoing clinical trial by University of Colorado Cancer Center investigators is evaluating the ability of an inhaled form of the pulmonary hypertension drug iloprost to prevent lung cancer.

Released: 12-Jun-2017 12:05 PM EDT
Metastatic Breast Cancer Cells Use Hedgehog to ‘Evilize’ Docile Neighbors
University of Colorado Cancer Center

University of Colorado Cancer Center study pinpoints promising link in the chain of hedgehog signaling that, when broken, could reduce the metastatic potential of breast cancer.

31-May-2017 5:05 PM EDT
CONNECT Registry Shows Only 9 Percent Compliance with Genetic Testing Guidelines for Aml
University of Colorado Cancer Center

Study presented at ASCO 2017 shows that only 9 percent of 259 evaluated AML patients received all seven of the NCCN-recommended genetic tests.

31-May-2017 4:05 PM EDT
Dasatinib Excels in Worldwide Phase II Trial Against Pediatric CML
University of Colorado Cancer Center

Worldwide phase II clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 show the promise of the second-generation drug dasatinib against pediatric CML. Of 113 pediatric patients studied, 75 percent of patients who had previously failed or did not tolerate imatinib saw progression-free survival 48 months after starting treatment with dasatinib.

Released: 17-May-2017 11:05 AM EDT
Brigatinib First Drug to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib
University of Colorado Cancer Center

FDA approves brigatinib as a second-line therapy for ALK-positive non-small cell lung cancer

Released: 16-May-2017 12:45 PM EDT
New Clinical Trial Framework Tests ‘Natural’ Cures for Cancer
University of Colorado Cancer Center

A University of Colorado Cancer Center clinical trial is now recruiting prostate cancer patients who would otherwise be on a watch-and-wait protocol to test the ability of grape seed extract to slow the rise of prostate-specific antigen (PSA), a common marker of prostate cancer progression.

Released: 15-May-2017 12:00 PM EDT
Breakthrough Study Stops Fat-Eating Prostate Cancer Cells
University of Colorado Cancer Center

Patients with castration resistant prostate cancer (CRPC) usually have a poor prognosis. In part, this is due to the cancer’s ability to resist anti-androgen therapy. A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer’s sensitivity to the anti-androgen drug enzalutamide.

Released: 19-Apr-2017 10:05 AM EDT
Malaria Drug Successfully Treats 26-Year-Old Brain Cancer Patient
University of Colorado Cancer Center

Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy

Released: 4-Apr-2017 4:05 PM EDT
AACR: Phase II Trial Shows Rice Bran Promotes Microbiome Diversity, Slows Growth of Colorectal Cancer Cells
University of Colorado Cancer Center

After 4-week trial of added rice bran, navy bean powder or neither, both the rice bran and navy bean groups showed increased dietary fiber, iron, zinc, thiamin, niacin, vitamin B6, folate, and alpha-tocopherol. The rice bran group also showed increased microbiome richness and diversity. When researchers treated colorectal cancer cells with stool extracts from these groups, they saw reduced cell growth from the groups that had increased rice bran and navy bean consumption.

14-Mar-2017 2:05 PM EDT
New Driver, Target in Advanced Mucosal Melanoma
University of Colorado Cancer Center

A University of Colorado Cancer Center study published March 15, 2017 in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype.

Released: 8-Mar-2017 11:05 AM EST
Women More Likely to Follow Through with Breast Screening Recommendations When Informed Directly
University of Colorado Cancer Center

Women at high risk for breast cancer who received a letter informing them of their options for additional imaging with contrast-enhanced MRI of the breast (in addition to a letter sent to their primary care physician) were more likely to return to the center for additional screening with MRI.

Released: 7-Mar-2017 4:30 PM EST
Early Deaths From Childhood Cancer Up to 4 Times More Common Than Previously Reported
University of Colorado Cancer Center

Treatments for childhood cancers have improved to the point that 5-year survival rates are over 80 percent. However, one group has failed to benefit from these improvements, namely children who die so soon after diagnosis that they are not able to receive treatment, or who receive treatment so late in the course of their disease that it is destined to fail.

Released: 10-Jan-2017 1:05 PM EST
Tucatinib (ONT-380) Progressing in Pivotal Trial Against HER2+ Breast Cancer
University of Colorado Cancer Center

Twenty-seven percent of 50 heavily pretreated patients with stage IV breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.

16-Dec-2016 1:40 PM EST
How to Keep Nanoparticle "Caterpillars" Safe From The "Crows" of the Immune System
University of Colorado Cancer Center

A University of Colorado Cancer Center paper published today in the journal Nature Nanotechnology details how the immune system recognizes nanoparticles, potentially paving the way to counteract or avoid this detection.

Released: 15-Nov-2016 6:30 PM EST
Crowdsourcing a Better Prostate Cancer Prediction Tool
University of Colorado Cancer Center

Prediction model created by "research parasites" published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer

Released: 31-Oct-2016 3:05 PM EDT
Less Than Half of Cervical Cancer Patients Receive Standard-of-Care Treatment
University of Colorado Cancer Center

University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment, most often lacking brachytherapy.

Released: 27-Oct-2016 1:05 PM EDT
Cancer Sequencing Results Differ Based on Genetic Background of Comparison Genome
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that comparing cancer cell sequencing results to published reference genomes may be less accurate than comparing to healthy cell from same organism.

14-Sep-2016 2:00 PM EDT
Seven-Year Study Pays Off with ‘Most Detailed’ Picture of Head and Neck Cancer Stem Cells to Date
University of Colorado Cancer Center

"After chemo, PI3K helps the cell shut down and weather the storm. Then when the chemo is gone, PI3K helps cancer stem cells start back up again," says University of Colorado Cancer Center investigator, Antonio Jimeno, MD, PhD.

Released: 9-Sep-2016 11:05 AM EDT
Double Negative Leads to Big Positive Against Bladder Cancer Metastasis
University of Colorado Cancer Center

New understanding stops bladder cancer's ability to stop the tumor-suppressing gene RhoDGI2, thus allowing its initial action to proceed.

Released: 29-Aug-2016 2:05 PM EDT
Study Uncovers Molecular Switch That May Sensitize Triple-Negative Breast Cancers to Immunotherapy
University of Colorado Cancer Center

University of Colorado Cancer Center investigators unpack the mechanism of investigational drug, AMPI-109, showing its inactivation of PRL-3 flips an important switch on triple-negative breast cancer.

Released: 25-Aug-2016 3:05 PM EDT
In Sub-Saharan Africa, Cancer Can Be an Infectious Disease
University of Colorado Cancer Center

University of Colorado Cancer Center researcher shows that women who contract malaria while pregnant may have children with an increased risk of Burkitt's lymphoma.


Showing results 51–100 of 203


close
0.22238